clinical trial · NCT05468697
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
Merck Sharp & Dohme LLC·phase2·active not recruiting·n = 60
Renal Cell CarcinomaBelzutifanPalbociclib
brief summary
The purpose of this study is to evaluate the efficacy and safety of belzutifan monotherapy and belzutifan plus palbociclib combination therapy in participants with advanced clear-cell renal cell carcinoma (ccRCC) who experienced disease progression on or after receiving prior therapy. The study will establish the safety of belzutifan plus palbociclib and determine a recommended dosage of palbociclib for the combination therapy by ascending dose escalation.
started
Aug 10, 2022
primary completion
Dec 22, 2026
completion
Dec 22, 2026
last updated
Oct 27, 2026
official title
A Multicenter, Open-label, Randomized, Phase 1/2 Study of Belzutifan in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol